529 related articles for article (PubMed ID: 16730266)
1. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
[TBL] [Abstract][Full Text] [Related]
2. Rational development of tumour antigen-specific immunization in melanoma.
Gajewski TF; Fallarino F
Ther Immunol; 1995 Aug; 2(4):211-25. PubMed ID: 9358613
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
4. Tumor antigens and tumor vaccines: peptides as immunogens.
Slingluff CL
Semin Surg Oncol; 1996; 12(6):446-53. PubMed ID: 8914209
[TBL] [Abstract][Full Text] [Related]
5. T-cell-based immunotherapy of melanoma: what have we learned and how can we improve?
Campoli M; Ferrone S
Expert Rev Vaccines; 2004 Apr; 3(2):171-87. PubMed ID: 15056043
[TBL] [Abstract][Full Text] [Related]
6. Melanoma cancer vaccines and anti-tumor T cell responses.
Vujanovic L; Butterfield LH
J Cell Biochem; 2007 Oct; 102(2):301-10. PubMed ID: 17647270
[TBL] [Abstract][Full Text] [Related]
7. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.
Engelhard VH; Bullock TN; Colella TA; Mullins DW
Cancer J; 2000 May; 6 Suppl 3():S272-80. PubMed ID: 10874498
[TBL] [Abstract][Full Text] [Related]
8. Melacine: an allogeneic melanoma tumor cell lysate vaccine.
Sosman JA; Sondak VK
Expert Rev Vaccines; 2003 Jun; 2(3):353-68. PubMed ID: 12903801
[TBL] [Abstract][Full Text] [Related]
9. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
[TBL] [Abstract][Full Text] [Related]
10. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
11. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
[TBL] [Abstract][Full Text] [Related]
12. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Hibbitts S; Murphy C; Johansen N; Grosh WW; Yamshchikov GV; Neese PY; Patterson JW; Fink R; Rehm PK
Clin Cancer Res; 2007 Nov; 13(21):6386-95. PubMed ID: 17975151
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell vaccines in melanoma: from promise to proof?
Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
[TBL] [Abstract][Full Text] [Related]
14. Melanoma vaccines.
Chapman PB
Semin Oncol; 2007 Dec; 34(6):516-23. PubMed ID: 18083375
[TBL] [Abstract][Full Text] [Related]
15. Development of optimized cryptic peptides for immunotherapy.
Menez-Jamet J; Kosmatopoulos K
IDrugs; 2009 Feb; 12(2):98-102. PubMed ID: 19204883
[TBL] [Abstract][Full Text] [Related]
16. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
17. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
18. Vaccination: role in metastatic melanoma.
Pilla L; Valenti R; Marrari A; Patuzzo R; Santinami M; Parmiani G; Rivoltini L
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1305-18. PubMed ID: 16925496
[TBL] [Abstract][Full Text] [Related]
19. The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma.
Anichini A; Vegetti C; Mortarini R
Cancer Immunol Immunother; 2004 Oct; 53(10):855-64. PubMed ID: 15175905
[TBL] [Abstract][Full Text] [Related]
20. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens.
Bleifuss E; Bendz H; Sirch B; Thompson S; Brandl A; Milani V; Graner MW; Drexler I; Kuppner M; Katsanis E; Noessner E; Issels RD
Int J Hyperthermia; 2008 Dec; 24(8):623-37. PubMed ID: 18608582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
